| 摘要 |
PROBLEM TO BE SOLVED: To provide an agent for preventing and treating intrahepatic stone, having excellent effects of enhancing the expression of human MDR3 on the pleural membrane of the bile duct, and accelerating the transportation of phospholipids to the bile duct, and to provide an agent for preventing the relapse thereof. SOLUTION: The medicinal composition containsα-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid (general name: bezafibrate) represented by the formula, or a pharmacologically acceptable salt thereof as an active ingredient. For example, when the bezafibrate of an active ingredient is orally administered, the dose per adult per day is 100-1,000 mg, preferably 400-600 mg, and the dose may be increased or decreased according to the symptom. COPYRIGHT: (C)2004,JPO
|
